FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017094717> ?p ?o ?g. }

• W2017094717 endingPage "215" @default.
• W2017094717 startingPage "207" @default.
• W2017094717 abstract "Background: In the pathogenesis of CHF neurohormonal changes, in particular, changes of activity of sympathetic nervous system (SNS) occupies an important position. For this reason, researchers concentrated on the use β-blockers in therapy of patients with CHF. They reduce heart rate, improve diastolic function of the myocardium, reduce secretion of renin and restore the sensitivity of β- adrenoreceptors to its regulatory influences. We studied the influence of the 3^rdgeneration betaadrenoblocker – Carvedilol in patients with CHF- including clinical efficacy and reduction of oxidative stress. Methods: The study was conducted in Saint-Petersburg State Medical University, from January 2000 to June 2000. 37 patients (33 male and 4 female) with CHF class III or IV despite receiving standard therapy of heart failure were enrolled in the study for the treatment with Carvedilol. All of the patients received Carvedilol for 6 months at a dose of 12.5-50mg/day with standard therapy of Heart Failure, which was not changed during next 6 months. Results: The average age of the patients was 56.8±2.3 years. The cause of CHF was IHD. 34 patients had chronic stable angina (CCS class II-IV). The majority of the patients had a history of myocardial infarction (91.8%); of these 73.5% of the patients had a history of repeated MI. Hypertension stage 2 and 3 was associated in 32.4% patients.Long-term therapy with Carvedilol led to improvement of the clinical status of the patients. After 6 months therapy with Carvedilol frequency of hospitalization was significantly reduced (1.36±0.23 vs. 0.33±0.1; p<0,01). The patients were symptomatically improved after 6 months therapy with Carvedilol. There was a tendency of reduction of LV mass by 12.1% (214.0±11.1 gm/m² vs. 188.1±10.8 gm/m², p<0.05). After treatment with Carvedilol there was significant increase in LVEF by 10% (30.0±1.5% to 33.0±0.1%; p<0.01) and increase in fractional shortening of LV by 22.2% (from 17.25±1.14 vs. 21.09±1.25; p<0.01). There was a significant reduction in plasma MDA, indicator of oxidative stress, in comparison with the baseline data. Conclusion: Carvedilol therapy in patients with Chronic heart failure improves clinical symptoms of patients with improvement in systolic & diastolic function of LV. Carvedilol also reduces oxidative stress in patients with heart failure. Keywords: Carvedilol, Heart failure, Ischaemic heart disease DOI: http://dx.doi.org/10.3329/cardio.v1i2.8240 Cardiovasc. j. 2009; 1(2): 207-215" @default.
• W2017094717 created "2016-06-24" @default.
• W2017094717 creator A5004613157 @default.
• W2017094717 creator A5032902565 @default.
• W2017094717 creator A5033898858 @default.
• W2017094717 date "1970-01-01" @default.
• W2017094717 modified "2023-09-25" @default.
• W2017094717 title "Clinical Efficacy of Carvedilol In Treatment of Patients With Ischemic Heart Disease and Chronic Heart Failure" @default.
• W2017094717 cites W1483108854 @default.
• W2017094717 cites W1524057507 @default.
• W2017094717 cites W1602123692 @default.
• W2017094717 cites W1972253696 @default.
• W2017094717 cites W1974311112 @default.
• W2017094717 cites W1977648865 @default.
• W2017094717 cites W1981079849 @default.
• W2017094717 cites W1985923799 @default.
• W2017094717 cites W1999879517 @default.
• W2017094717 cites W2004923834 @default.
• W2017094717 cites W2006705499 @default.
• W2017094717 cites W2007424418 @default.
• W2017094717 cites W2016532277 @default.
• W2017094717 cites W2016584191 @default.
• W2017094717 cites W2022858910 @default.
• W2017094717 cites W2036718044 @default.
• W2017094717 cites W203770522 @default.
• W2017094717 cites W2040472033 @default.
• W2017094717 cites W2043598433 @default.
• W2017094717 cites W2045638363 @default.
• W2017094717 cites W2051653151 @default.
• W2017094717 cites W2063115631 @default.
• W2017094717 cites W2066125362 @default.
• W2017094717 cites W2068385402 @default.
• W2017094717 cites W2070759302 @default.
• W2017094717 cites W2071371689 @default.
• W2017094717 cites W2078395346 @default.
• W2017094717 cites W2088138316 @default.
• W2017094717 cites W2090269451 @default.
• W2017094717 cites W2090881549 @default.
• W2017094717 cites W2093857799 @default.
• W2017094717 cites W2095930974 @default.
• W2017094717 cites W2123263258 @default.
• W2017094717 cites W2123495845 @default.
• W2017094717 cites W2125109199 @default.
• W2017094717 cites W2128439338 @default.
• W2017094717 cites W2138459630 @default.
• W2017094717 cites W2162092150 @default.
• W2017094717 cites W2263857556 @default.
• W2017094717 cites W2326508838 @default.
• W2017094717 cites W2407599978 @default.
• W2017094717 cites W2412485238 @default.
• W2017094717 cites W77897662 @default.
• W2017094717 cites W2008918262 @default.
• W2017094717 cites W2404706969 @default.
• W2017094717 cites W2460702456 @default.
• W2017094717 doi "https://doi.org/10.3329/cardio.v1i2.8240" @default.
• W2017094717 hasPublicationYear "1970" @default.
• W2017094717 type Work @default.
• W2017094717 sameAs 2017094717 @default.
• W2017094717 citedByCount "0" @default.
• W2017094717 crossrefType "journal-article" @default.
• W2017094717 hasAuthorship W2017094717A5004613157 @default.
• W2017094717 hasAuthorship W2017094717A5032902565 @default.
• W2017094717 hasAuthorship W2017094717A5033898858 @default.
• W2017094717 hasBestOaLocation W20170947171 @default.
• W2017094717 hasConcept C126322002 @default.
• W2017094717 hasConcept C164705383 @default.
• W2017094717 hasConcept C2778198053 @default.
• W2017094717 hasConcept C2778425758 @default.
• W2017094717 hasConcept C2780591200 @default.
• W2017094717 hasConcept C500558357 @default.
• W2017094717 hasConcept C57900726 @default.
• W2017094717 hasConcept C71924100 @default.
• W2017094717 hasConcept C84393581 @default.
• W2017094717 hasConceptScore W2017094717C126322002 @default.
• W2017094717 hasConceptScore W2017094717C164705383 @default.
• W2017094717 hasConceptScore W2017094717C2778198053 @default.
• W2017094717 hasConceptScore W2017094717C2778425758 @default.
• W2017094717 hasConceptScore W2017094717C2780591200 @default.
• W2017094717 hasConceptScore W2017094717C500558357 @default.
• W2017094717 hasConceptScore W2017094717C57900726 @default.
• W2017094717 hasConceptScore W2017094717C71924100 @default.
• W2017094717 hasConceptScore W2017094717C84393581 @default.
• W2017094717 hasIssue "2" @default.
• W2017094717 hasLocation W20170947171 @default.
• W2017094717 hasOpenAccess W2017094717 @default.
• W2017094717 hasPrimaryLocation W20170947171 @default.
• W2017094717 hasRelatedWork W1864361583 @default.
• W2017094717 hasRelatedWork W1979467917 @default.
• W2017094717 hasRelatedWork W2049397185 @default.
• W2017094717 hasRelatedWork W2125804349 @default.
• W2017094717 hasRelatedWork W2127666157 @default.
• W2017094717 hasRelatedWork W2167036398 @default.
• W2017094717 hasRelatedWork W2237746437 @default.
• W2017094717 hasRelatedWork W2371322233 @default.
• W2017094717 hasRelatedWork W2374022257 @default.
• W2017094717 hasRelatedWork W2399063111 @default.
• W2017094717 hasVolume "1" @default.
• W2017094717 isParatext "false" @default.

• next